Odyssey Health Enters Material Definitive Agreement

TL;DR

Odyssey Health signed a big deal on Oct 14th.

AI Summary

Odyssey Health, Inc. announced on October 14, 2025, that it entered into a material definitive agreement. The company, formerly known as Odyssey Group International, Inc., is incorporated in Nevada and its principal executive offices are located in Las Vegas, NV.

Why It Matters

This filing indicates a significant business development for Odyssey Health, Inc., potentially impacting its future operations and financial standing.

Risk Assessment

Risk Level: medium — Entering into a material definitive agreement can introduce new risks and opportunities that are not yet fully understood.

Key Players & Entities

• Odyssey Health, Inc. (company) — Registrant
• Odyssey Group International, Inc. (company) — Former Company Name
• October 14, 2025 (date) — Date of earliest event reported
• Nevada (jurisdiction) — State of incorporation
• Las Vegas, NV (location) — Address of principal executive offices
• 702-780-6559 (phone_number) — Registrant's telephone number

FAQ

Key Financial Figures

• $0.001 — nge on Which Registered Common Stock ($0.001 par value) ODYY OTCQB Indicate by c

Filing Documents

• odyssey_8k.htm (8-K) — 30KB
• odyssey_ex1001.htm (EX-10.1) — 132KB
• odyssey_ex9901.htm (EX-99.1) — 11KB
• 0001683168-25-007644.txt ( ) — 365KB
• odyy-20251014.xsd (EX-101.SCH) — 3KB
• odyy-20251014_lab.xml (EX-101.LAB) — 33KB
• odyy-20251014_pre.xml (EX-101.PRE) — 22KB
• odyssey_8k_htm.xml (XML) — 3KB

01

Item 1.01. Entry into a Material Definitive Agreement. On October 14, 2025, Odyssey Health, Inc., a Nevada corporation ("Odyssey" the "Company") entered into a Master Technology and Sub-license Agreement (the "Agreement") with NeuRX Health, Inc. ("NeuRX"). Pursuant to the Agreement, the Company, has signed a sub-licensing agreement for exclusive, worldwide rights to the BreastCheck, a non-invasive test for breast abnormalities. The definitive agreement, managed through its subsidiary Odyssey Medical Devices, Inc., is subject to certain closing conditions. The Agreement also includes customary representations, warranties, and covenants. The Agreement also contains indemnification rights for each of the Company and NeuRX for breaches of representations, warranties, and covenants. The Agreement contemplates the execution of certain customary ancillary agreements and documents to be delivered at Closing. The above description of the Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Agreement, a copy of which is attached hereto as Exhibit 10.1 and is incorporated herein by reference to this 8-K. The Agreement has been filed as an exhibit to this Current Report on Form 8-K to provide investors with information regarding the terms The Agreement involves various risks, including without limitation those set forth in Item 8.01 below.

Forward-Looking Statements

Forward-Looking Statements This communication contains "forward-looking statements" within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, including without limitation statements regarding the ability of the Company to timely and successfully close on the sub-license agreement. These forward-looking statements are based on management's beliefs and assumptions and information currently available. The words "believe," "expect," "anticipate," "intend," "estimate," "project" and similar expressions that do not relate solely to historical matters identify forward-looking statements. Investors should be cautious in relying on forward-looking statements because they are subject to a variety of risks, uncertainties, and other factors that could cause actual results to differ materially from those expressed in any such forward-looking statements. These factors include, but are not limited to: the Company's ability to advance the development and commercialization of the BreastCheck under the timelines and in accord with the milestones projected; the Company's ability to raise capital and obtain funding, non-dilutive or otherwise, for the development and commercialization of the BreastCheck ; the Company's ability to obtain, maintain and enforce necessary patent and other intellectual property protection; the Company's expectations as to the outcome of the potential benefits, effectiveness and safety of the BreastCheck including as to administration, manufacturing, distribution and general economic and market conditions and risks, as well as other uncertainties described in our filings with the U.S. Securities and Exchange Commission. All information set forth is as of the date hereof unless otherwise indicated. You should consider these factors in evaluating the forward-looking statements.

01

Item 8.01. Other Information. On October 16, 2025, the Company issued a press release announcing the signing of the Master Technology and Sub-license Agreement. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K.

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits. Number Exhibit 10.1 Master Technology and Sub-license Agreement between Odyssey and NeuRX 99.1 Press Release dated October 16, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 2

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Odyssey Health, Inc. Date: October 17, 2025 By: /s/ Joseph Michael Redmond Joseph Michael Redmond Chief Executive Officer 3

View Full Filing

View this 8-K filing on SEC EDGAR